Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder

Philadelphia, PA, November 29, 2022– Mebias Discovery Inc., a biotechnology company focused on drug discovery targeting G-protein coupled receptors, today announces its Investigational New Drug, MEB-1170, has entered Phase I human clinical...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials